Genentech Avastin Label Adds Third-Line Data Showing Minimal Efficacy
This article was originally published in The Pink Sheet Daily
Executive Summary
NCI study of bevacizumab demonstrated a 1% response rate in refractory metastatic colorectal cancer when combined with 5-FU/LV.